Information Provided By: 
Fly News Breaks for October 5, 2016
CPRX
Oct 5, 2016 | 06:03 EDT
Piper Jaffray analyst Charles Duncan upgraded Catalyst Pharmaceuticals to Overweight saying he sees reduced clinical risk for Firdapse's lead indication in LEMS based on finalized design of the second Phase III set to begin this quarter. The analyst also believes regulatory risk has been mitigated by close interaction with the FDA on trial design. Duncan thinks the program will "soon be back on track and poised for 2017 value creation." He upped his price target for Catalyst shares to $4 from $1.
News For CPRX From the Last 2 Days
There are no results for your query CPRX
